FDG PET in the Evaluation of Mild Cognitive Impairment and Early Dementia

  • Lisa Mosconi
  • Daniel H.S. Silverman

Alzheimer’s disease (AD) is the most common form of dementia in mid- to late life and one of the most serious health problems in the industrialized world. The elderly are the fastest growing part of the population, and increases in life expectancy will inevitably lead to a further increase in the prevalence of AD. Moreover, age-associated cognitive impairments affecting 10 times as many individuals. 1 The risk of developing AD doubles approximately every 5 years between the ages of 65 and 85 years, and as the baby boomer generation ages, it is estimated that in 30 years 15 to 20 million elderly nationwide may have some cognitive disability. 1, 2 The demographics of aging thus suggest a great need to diagnose AD accurately and distinguish it specifically from the many other possible causes of cognitive impairment. As strategies to delay disease progression and possibly prevent or offset the onset of AD are under development, 3 it is extremely important to recognize individuals at high risk for developing AD who may particularly benefit from early therapeutic interventions. Remarkable progress has been made in the understanding of the cascade of molecular events leading to AD. In the last decade, genetic abnormalities have been identified, new pathophysiologic mechanisms discovered, therapeutic agents approved, and diagnostic tests developed. Nonetheless, fundamental questions remain unanswered and the lack of specific biological markers hinders the management of AD. With the development of specific and effective prevention treatments, improved early detection of AD will be increasingly critical for medical care.


Mild Cognitive Impairment Entorhinal Cortex Posterior Cingulate Cortex Mild Cognitive Impairment Patient Amnestic Mild Cognitive Impairment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    1. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88:1337–1342.PubMedGoogle Scholar
  2. 2.
    2. Petersen RC, Smith GE, Waring SC. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303–308.PubMedGoogle Scholar
  3. 3.
    3. Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer’s disease: current status and new perspectives. Lancet Neurol 2003;2:539–547.PubMedGoogle Scholar
  4. 4.
    4. Ball MJ, Hachinski V, Fox A. A new definition of Alzheimer’s disease: a hippocampal dementia. Lancet 1985;1:14–16.PubMedGoogle Scholar
  5. 5.
    5. Manolio TA, Kronmal RA, Burke GL. Magnetic resonance abnormalities and cardiovascular disease in older adults. The Cardiovascular Health Study. Stroke 1994;25:318–327.PubMedGoogle Scholar
  6. 6.
    6. Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol 1999;45:358–368.PubMedGoogle Scholar
  7. 7.
    7. Morrison JH, Hof PR. Life and death of neurons in the aging brain. Science 1997;278:412–419.PubMedGoogle Scholar
  8. 8.
    8. Braak H, Braak E. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol 1996;92:197–201.PubMedGoogle Scholar
  9. 9.
    9. Delacourte A, David JP, Sergeant N. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease. Neurology 1999;52:1158–1165.PubMedGoogle Scholar
  10. 10.
    10. Morris JC, Storandt M, McKeel DW. Cerebral amyloid deposition and diffuse plaques in “normal” aging: evidence for presymptomatic and very mild Alzheimer’s disease. Neurology 1996;46:707–719.PubMedGoogle Scholar
  11. 11.
    11. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239–259.PubMedGoogle Scholar
  12. 12.
    12. Mesulam MM. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron 1999;24:521–529.PubMedGoogle Scholar
  13. 13.
    13. Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer’s disease. Neurology 1992;42:1681–1688.PubMedGoogle Scholar
  14. 14.
    14. Giannakopoulos P, Hof PR, Mottier S. Neuropathological changes in the cerebral cortex of 1258 cases from a geriatric hospital: retrospective clinicopathological evaluation of a 10-year autopsy population. Acta Neuropathol 1994;87:456–468.PubMedGoogle Scholar
  15. 15.
    15. Ulrich J. Alzheimer changes in nondemented patients younger than sixty-five: possible early stages of Alzheimer’s disease and senile dementia of Alzheimer type. Ann Neurol 1985;17:273–277.PubMedGoogle Scholar
  16. 16.
    16. Lambert MP, Barlow AK, Chromy BA. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998;95:6448–6453.PubMedGoogle Scholar
  17. 17.
    17. Gomez-Isla T, Hollister R, West H. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann Neurol 1997;41:17–24.PubMedGoogle Scholar
  18. 18.
    18. Terry RD, Masliah E, Salmon DP. Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30:572–580.PubMedGoogle Scholar
  19. 19.
    19. Jernigan TL, Archibald SL, Berhow MT. Cerebral structure on MRI, Part I: Localization of age-related changes. Biol Psychiatry 1991;29:55–67.PubMedGoogle Scholar
  20. 20.
    20. Thompson PM, Hayashi KM, de Zubicaray GI. Dynamics of gray matter loss in Alzheimer's disease. J Neurosci 2003;23:994–1005.PubMedGoogle Scholar
  21. 21.
    21. Kesslak JP, Nalcioglu O, Cotman CW. Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer’s disease. Neurology 1991;41:51–54.PubMedGoogle Scholar
  22. 22.
    22. Jack CR Jr, Petersen RC, O’Brien PC. MR-based hippocampal volumetry in the diagnosis of Alzheimer’s disease. Neurology 1992;42:183–188.PubMedGoogle Scholar
  23. 23.
    23. Killiany RJ, Moss MB, Albert MS. Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer’s disease. Arch Neurol 1993;50:949–954.PubMedGoogle Scholar
  24. 24.
    24. Convit A, de Leon MJ, Tarshish C. Hippocampal volume losses in minimally impaired elderly. Lancet 1995;345:266.PubMedGoogle Scholar
  25. 25.
    25. de Toledo-Morrell L, Sullivan MP, Morrell F. Alzheimer’s disease: in vivo detection of differential vulnerability of brain regions. Neurobiol Aging 1997;18:463–468.Google Scholar
  26. 26.
    26. Jack CR Jr, Petersen RC, Xu YC. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer’s disease. Neurology 1997;49:786–794.PubMedGoogle Scholar
  27. 27.
    27. Convit A, de Leon MJ, Tarshish C. Specific hippocampal volume reductions in individuals at risk for Alzheimer’s disease. Neurobiol Aging 1997;18:131–138.PubMedGoogle Scholar
  28. 28.
    28. Bobinski M, Wegiel J, Tarnawski M. Relationships between regional neuronal loss and neurofibrillary changes in the hippocampal formation and duration and severity of Alzheimer disease. J Neuropath Exp Neurol 1997;56:414–420.PubMedGoogle Scholar
  29. 29.
    29. Bobinski M, de Leon MJ, Wegiel J. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer’s disease. Neuroscience 2000;95:721–725.PubMedGoogle Scholar
  30. 30.
    30. Saura CA, Choi S, Beglopoulos V. Loss of presenilin function in the adult brain causes memory and synaptic plasticity impairments and age-dependent neurodegeneration. Neuron 2004;42:23–36.PubMedGoogle Scholar
  31. 31.
    31. Clark DD, Sokoloff L. Circulation and energy metabolism of the brain. In: Siegel GJ, Agranoff BW, Albers RW, Basic Neurochemistry. Molecular, Cellular and Medical Aspects. Philadelphia: Lippincott-Raven, 1999:637–670.Google Scholar
  32. 32.
    32. Attwell D, Iadecola C. The neural basis of functional brain imaging signals. Trends Neurosci 2002;25:621–625.PubMedGoogle Scholar
  33. 33.
    33. Magistretti PJ, Pellerin L, Rothman DL. Energy on demand. Science 1999;283:496–497.PubMedGoogle Scholar
  34. 34.
    34. Fonnum F. Glutamate: a neurotransmitter in mammalian brain. J Neurochem 1984;42:1–11.PubMedGoogle Scholar
  35. 35.
    35. Herholz K. PET studies in dementia. Ann Nucl Med 2003;17:79–89.PubMedGoogle Scholar
  36. 36.
    36. Bartlett EJ, Barouche F, Brodie JD. Stability of resting deoxyglucose metabolic values in PET studies of schizophrenia. Psych Res Neuroimaging 1991;40:11–20.Google Scholar
  37. 37.
    37. Mazziotta JC, Phelps ME. Positron emission tomography studies of the brain. In: Phelps ME, Mazziotta JC, Schelbert H, Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and Heart. New York: Raven, 1986:493–579.Google Scholar
  38. 38.
    38. Mielke R, Kessler J, Szelies B. Normal and pathological aging—findings of positron-emission-tomography. J Neural Transm 1998;105:821–837.PubMedGoogle Scholar
  39. 39.
    39. Murphy DGM, Bottomley PA, Salerno JA. An in vivo study of phosphorus and glucose metabolism in Alzheimer’s disease using magnetic resonance spectroscopy and PET. Arch Gen Psychiatry 1993;50:341–349.PubMedGoogle Scholar
  40. 40.
    40. Smith GS, de Leon MJ, George AE. Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer’s disease: pathophysiologic implications. Arch Neurol 1992;49:1142–1150.PubMedGoogle Scholar
  41. 41.
    41. Jagust WJ, Friedland RP, Budinger TF. Longitudinal studies of regional cerebral metabolism in Alzheimer’s disease. Neurology 1988;38:909–912.PubMedGoogle Scholar
  42. 42.
    42. Alexander GE, Chen K, Pietrini P. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer’s disease treatment studies. Am J Psychiatry 2002;159:738–745.PubMedGoogle Scholar
  43. 43.
    43. Nordberg A, Lilja A, Lindqvist H. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualised by PET. Neurobiol Aging 1992;13:747–758.PubMedGoogle Scholar
  44. 44.
    44. Tuszynski MH, Thal L, Pay M. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005;11:551–555.PubMedGoogle Scholar
  45. 45.
    45. de Leon MJ, McRae T, Rusinek H. Cortisol reduces hippocampal glucose metabolism in normal elderly but not in Alzheimer’s disease. J Clin Endocrinol Metab 1997;82:3251–3259.PubMedGoogle Scholar
  46. 46.
    46. Ouchi Y, Nobezawa S, Okada H. Altered glucose metabolism in the hippocampal head in memory impairment. Neurology 1998;51:136–142.PubMedGoogle Scholar
  47. 47.
    47. de Leon MJ, Convit A, Wolf OT. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001;98:10966–10971.PubMedGoogle Scholar
  48. 48.
    48. De Santi S, de Leon MJ, Rusinek H. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001;22:529–539.PubMedGoogle Scholar
  49. 49.
    49. Nestor PJ, Fryer TD, Smielewski P. Limbic hypometabolism in Alzheimer’s disease and mild cognitive impairment. Ann Neurol 2003;54:343–351.PubMedGoogle Scholar
  50. 50.
    50. Mosconi L, Tsui WH, De Santi S. Reduced hippocampal metabolism in mild cognitive impairment and Alzheimer’s disease: automated FDG-PET image analysis. Neurology 2005;64:1860–1867.PubMedGoogle Scholar
  51. 51.
    51. Mosconi L, De Santi S, Li Y. Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer’s disease using FDG-PET. Eur J Nucl Med 2006;33:210–221.Google Scholar
  52. 52.
    52. Heiss W-D, Habedank B, Klein JC. Metabolic rates in small brain nuclei determined by high-resolution PET. J Nucl Med 2004;45:1811–1815.PubMedGoogle Scholar
  53. 53.
    53. Meltzer CC, Zubieta JK, Brandt J. Regional hypometabolism in Alzheimer’s disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology 1996;47:454–461.PubMedGoogle Scholar
  54. 54.
    54. Ibanez V, Pietrini P, Alexander GE. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer’s disease. Neurology 1999;50:1585–1593.Google Scholar
  55. 55.
    55. Petersen RC, Doody R, Kurz A. Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985–1992.PubMedGoogle Scholar
  56. 56.
    56. Silverman DH, Mosconi L, Ercoli L, et al. Positron emission tomography scans obtained for the evaluation of cognitive dysfunction. Semin Nucl Med 2008;38:251–61Google Scholar
  57. 57.
    57. Silverman DHS, Truong CT, Kim SK. Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. Mol Genet Metab 2003;80:350–355.PubMedGoogle Scholar
  58. 58.
    58. Schenk D, Barbour R, Dunn W. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173–177.PubMedGoogle Scholar
  59. 59.
    59. Silverman DHS, Gambhir SS, Huang HW. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. J Nucl Med 2002;43:253–266.PubMedGoogle Scholar
  60. 60.
    60. Reiman EM, Caselli RJ, Chen K. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer’s disease. Proc Natl Acad Sci USA 2001;98:3334–3339.PubMedGoogle Scholar
  61. 61.
    61. Tanzi R, Bertram L. New frontiers in Alzheimer’s disease genetics. Neuron 2001;32:181–184.PubMedGoogle Scholar
  62. 62.
    62. Petersen RC, Stevens JC, Ganguli M. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133–1142.PubMedGoogle Scholar
  63. 63.
    63. Corder EH, Saunders AM, Strittmatter WJ. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993;261:921–923.PubMedGoogle Scholar
  64. 64.
    64. Fox NC, Warrington EK, Rossor MN. Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer’s disease. Lancet 1999;353:2125.PubMedGoogle Scholar
  65. 65.
    65. Fox NC, Crum WR, Scahill RI. Imaging of onset and progression of Alzheimer’s disease with voxel-compression mapping of serial magnetic resonance images. Lancet 2001;358:201–205.PubMedGoogle Scholar
  66. 66.
    66. Scahill RI, Schott JM, Stevens JM. Mapping the evolution of regional atrophy in Alzheimer’s disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci USA 2002;99:4703–4707.PubMedGoogle Scholar
  67. 67.
    67. Kennedy AM, Newman SK, Frackowiak RS. Chromosome 14 linked familial Alzheimer’s disease. A clinico-pathological study of a single pedigree. Brain 1995;118:185–205.PubMedGoogle Scholar
  68. 68.
    68. Kennedy AM, Frackowiak RSJ, Newman SK. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci Lett 1995;186:17–20.PubMedGoogle Scholar
  69. 69.
    69. Jagust WJ. Functional imaging in dementia: an overview. J Clin Psychiatry 1994;55(Suppl):5–11.PubMedGoogle Scholar
  70. 70.
    70. Reed BR, Jagust WJ, Seab JP. Memory and regional cerebral blood flow in mildly symptomatic Alzheimer’s disease. Neurology 1989;39:1537–1539.PubMedGoogle Scholar
  71. 71.
    71. Powers WJ, Perlmutter JS, Videen TO. Blinded clinical evaluation of positron emission tomography for diagnosis of probable Alzheimer’s disease. Neurology 1992;42:765–770.PubMedGoogle Scholar
  72. 72.
    72. Small GW, Okonek A, Mandelkern MA. Age-associated memory loss: initial neuropsychological and cerebral metabolic findings of a longitudinal study. Int Psychogeriat 1994;6:23–44.Google Scholar
  73. 73.
    73. McKelvey R, Bergman H, Stern J. Lack of prognostic significance of SPECT abnormalities in non-demented elderly subjects with memory loss. Can J Neurol Sci 1999;26:23–28.PubMedGoogle Scholar
  74. 74.
    74. Minoshima S, Giordani B, Berent S. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 1997;42:85–94.PubMedGoogle Scholar
  75. 75.
    75. Herholz K, Nordberg A, Salmon E. Impairment of neocortical metabolism predicts progression in Alzheimer’s disease. Dementia Geriatr Cog Dis 1999;10:494–504.Google Scholar
  76. 76.
    76. Arnaiz E, Jelic V, Almkvist O. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. NeuroReport 2001;12:851–855.PubMedGoogle Scholar
  77. 77.
    77. Chetelat G, Desgranges B, De La Sayette V Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer’s disease. Neurology 2003;60:1374–1377.PubMedGoogle Scholar
  78. 78.
    78. Cohen G. Age differences in memory for texts: production deficiency or processing limitations? In: Light L, Burke D, Language, Memory and Aging. New York: Cambridge University Press, 1990:171–190.Google Scholar
  79. 79.
    79. Berent S, Giordani B, Foster N. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer’s disease. J Psychiatry Res 1999;33:7–16.Google Scholar
  80. 80.
    80. Drzezga A, Lautenschlager N, Siebner H. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study. Eur J Nucl Med Mol Imag 2003;30:1104–1113.Google Scholar
  81. 81.
    81. Mosconi L, Sorbi S, Nacmias B. Brain metabolic differences between sporadic and familial Alzheimer’s disease. Neurology 2003;61:1138–1140.PubMedGoogle Scholar
  82. 82.
    82. Drzezga A, Grimmer T, Riemenschneider M. Prediction of individual outcome in MCI by means of genetic assessment and 18F-FDG PET. J Nucl Med 2005;46:1625–1632.PubMedGoogle Scholar
  83. 83.
    83. Anchisi D, Borroni B, Franceschi M. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 2005;62:1728–1733.PubMedGoogle Scholar
  84. 84.
    84. Friston KJ, Holmes AP, Worsley KJ. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 1995;2:189–210.Google Scholar
  85. 85.
    85. Minoshima S, Frey KA, Koeppe RA. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995;36:1238–1248.PubMedGoogle Scholar
  86. 86.
    86. Small GW, Mazziotta JC, Collins MT. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995;273:942–947.PubMedGoogle Scholar
  87. 87.
    87. Reiman EM, Caselli RJ, Yun LS. Preclinical evidence of Alzheimer’s disease in persons homozygous for the E4 allele for apolipoprotein E. N Engl J Med 1996;334:752–758.PubMedGoogle Scholar
  88. 88.
    88. Small GW, Ercoli LM, Silverman DHS. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease. Proc Natl Acad Sci USA 2000;97:6037–6042.PubMedGoogle Scholar
  89. 89.
    89. Reiman EM, Chen K, Alexander GE. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proc Natl Acad Sci USA 2004;101:284–289.PubMedGoogle Scholar
  90. 90.
    90. Meltzer CC, Leal JP, Mayberg HS. Correction of PET data for partial volume effects in human cerebral cortex by MR imaging. J Comput Assist Tomogr 1990;14:561–570.PubMedGoogle Scholar
  91. 91.
    91. Jack CR, Peterson RC, Xu Y. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 2000;55:484–489.PubMedGoogle Scholar
  92. 92.
    92. Rusinek H, De Santi S, Frid D. Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. Radiology 2003;229:691–696.PubMedGoogle Scholar
  93. 93.
    93. Jack CR Jr, Shiung MM, Gunter JL. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004;62:591–600.PubMedGoogle Scholar
  94. 94.
    94. den Heijer T, Geerlings MI, Hoebeek FE. Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. Arch Gen Psychiatry 2006;63:57–62.Google Scholar
  95. 95.
    95. Hoffman JM, Hanson MW, Welsh KA. Interpretation variability of 18FDG-positron emission tomography studies in dementia. Invest Radiol 1996;31:316–322.PubMedGoogle Scholar
  96. 96.
    96. Masterman DL, Mendez MF, Fairbanks LA. Sensitivity, specificity, and positive predictive value of technetium 99-HMPAO SPECT in discriminating Alzheimer’s disease from other dementias. J Geriatr Psychiatry Neurol 1997;10:15–21.PubMedGoogle Scholar
  97. 97.
    97. Van Heertum RL, Tikofsky RS, Ruben AB. Dementia. In: Van Heertum RL, Tikofsky RS, Functional Cerebral SPECT and PET Imaging, 3rd ed. New York: Lippincott Williams & Wilkins, 2000:127–188.Google Scholar
  98. 98.
    98. Mielke R, Heiss WD. Positron emission tomography for diagnosis of Alzheimer’s disease and vascular dementia. J Neural Transm Suppl 1998;53:237–250.PubMedGoogle Scholar
  99. 99.
    99. Messa C, Perani D, Lucignani G. High-resolution technetium-99m-HMPAO SPECT in patients with probable Alzheimer’s disease: comparison with fluorine-18-FDG PET. J Nucl Med 1994;35:210–216.PubMedGoogle Scholar
  100. 100.
    100. Mielke R, Pietrzyk U, Jacobs A. HMPAO SPECT and FDG PET in Alzheimer’s disease and vascular dementia: comparison of perfusion and metabolic pattern. Eur J Nucl Med 1994;21:1052–1060.PubMedGoogle Scholar
  101. 101.
    101. Imabayashi E, Matsuda H, Asada T. Superiority of 3-dimensional stereotactic surface projection analysis over visual inspection in discrimination of patients with very early Alzheimer’s disease from controls using brain perfusion SPECT. J Nucl Med 2004;45:1450–1457.PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2009

Authors and Affiliations

  • Lisa Mosconi
    • 1
  • Daniel H.S. Silverman
    • 2
  1. 1.Department of PsychiatryNew York University School of MedicineNew YorkNY
  2. 2.Division of Biological Imaging; Department of Molecular and Medical PharmacologyUCLA Alzheimer’s Disease Center Imaging Core, David Geffen School of Medicine, University of CaliforniaLos AngelesCA

Personalised recommendations